CPC C07K 16/2878 (2013.01) [A61K 35/17 (2013.01); A61K 39/0011 (2013.01); A61P 35/00 (2018.01); C07K 14/00 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/283 (2013.01); A61K 38/00 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/31 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01)] | 11 Claims |
1. A chimeric antigen receptor (CAR) comprising:
a first antigen-binding domain that binds specifically to B-cell maturation antigen (BCMA), the first antigen binding domain comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 101, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 102, a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 103, VH CDR1 comprising the amino acid sequence of SEQ ID NO: 104, a VL VH CDR2 comprising the amino acid sequence of SEQ ID NO: 105, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 106;
a second antigen-binding domain that binds specifically to CD307e, the second antigen binding domain comprising a first set of CDRs, a second set of CDRs, or a third set of CDRs, wherein,
the first set of CDRs comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 107, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 108, a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 109, a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 110, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 111, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 112;
the second set of CDRs comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 119, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 120, a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 121, a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 122, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 123, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 124; and
the third set of CDRs comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 125, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 126, a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 127, a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 128, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 129, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 130;
a linker that is positioned between the first antigen-binding domain and the second antigen-binding domain;
a transmembrane domain comprising the amino acid sequence of SEQ ID NO: 48;
a hinge sequence that is positioned between the first antigen-binding domain and the transmembrane domain comprising the amino acid sequence of SEQ ID NO: 81;
a co-stimulatory domain comprising the amino acid sequence of SEQ ID NO: 93; and
an intracellular signaling domain comprising the amino acid sequence of SEQ ID NO: 85.
|